Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06168357

Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .

Role of ADC value and DWI in abbreviated MRI compared to post-contrast CT in follow-up of HCC after TACE.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Hepatocellular carcinoma (HCC) is the 5th most common cancer in the world and the most common in Egypt .

Trans-arterial chemoembolization (TACE) is the treatment recommended for unresectable HCC according to Barcelona clinic liver cancer staging and is widely used .

HCC is nourished only by the hepatic artery, so TACE causes ischemia and coagulative necrosis. However; viable neoplastic tissue residual may be seen after TACE. Assessment of post-TACE tumor response is important in determining treatment success and in guiding future therapy .

Many studies have assessed the diagnostic performance of multiphasic contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) in diagnosis of HCC with noted higher sensitivity of MRI compared to CT. CT or MRI are recommended for assessment of response after treatment as well .

Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) are functional MRI techniques that detect signal changes in tissues due to water proton motion. The intact membranes of viable tumor cells restrict water diffusion, whereas necrotic tumor cells with disrupted cell membranes exhibit increased water diffusion and which differentiate the biological activity of HCC

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who underwent TACE for unresectable HCC with patent portal vein based on Doppler, no ascites, and satisfactory liver function.

Age between 20-year old and 85-year old

Exclusion criteria

  • Estimated GFR less than 60 Previous history of severe allergic reaction to the iodinated contrast agent Patients with claustrophobia who can't undergo MR examination. Patients having cochlear implants or cardiac pacemaker

Treatment and study plan

Primary outcomes

  1. Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.

    Time frame: Baseline

    correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.

Study contacts

Contact information is provided by the study sponsor or research team.

Mostafa Ahmed Sayed, Lecturer

CONTACT

[email protected]

01092300511

Nour Mokhles Farah, Resident doctor

CONTACT

[email protected]

01212872901

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma Following Locoregional Treatment.

Important dates

Study start
2024
Primary completion
2025
Study completion
2027
First posted
Dec 13, 2023
Registry last updated
Dec 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.